Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

EYPT

EyePoint Inc

Mar 12 • 04:00PM ET

14.03

-0.89 -5.97 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY VRTX NBIX BMRN IONS SAGE RARE AGIO BLUE

| Held by: VTI IWM VXF IWN SCHA XPH VTWO PINK IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-3.16	Insider Own	12.26%	Shs Outstand	82.83M	Perf Week	-10.98%
Market Cap	1.17B	Forward P/E	-	EPS next Y	-3.57	Insider Trans	-1.16%	Shs Float	73.21M	Perf Month	2.26%
Enterprise Value	887.25M	PEG	-	EPS next Q	-0.82	Inst Own	90.59%	Short Float	14.85%	Perf Quarter	-17.86%
Income	-231.96M	P/S	37.31	EPS this Y	-1.62%	Inst Trans	16.85%	Short Ratio	7.74	Perf Half Y	3.54%
Sales	31.37M	P/B	3.80	EPS next Y	-10.77%	ROA	-59.29%	Short Interest	10.87M	Perf YTD	-23.21%
Book/sh	3.70	P/C	3.82	EPS next 5Y	28.18%	ROE	-72.19%	52W High	19.11 -26.58%	Perf Year	91.41%
Cash/sh	3.67	P/FCF	-	EPS past 3/5Y	-4.94% 2.18%	ROIC	-70.96%	52W Low	3.91 258.82%	Perf 3Y	479.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.83% -1.85%	Gross Margin	90.59%	Volatility	6.73% 8.64%	Perf 5Y	25.16%
Dividend TTM	-	EV/Sales	28.28	EPS Y/Y TTM	-36.74%	Oper. Margin	-775.96%	ATR (14)	1.19	Perf 10Y	-51.79%
Dividend Ex-Date	-	Quick Ratio	8.83	Sales Y/Y TTM	-27.50%	Profit Margin	-739.39%	RSI (14)	38.49	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	8.88	EPS Q/Q	-26.98%	SMA20	-11.98%	Beta	1.83	Target Price	37.42
Payout	-	Debt/Eq	0.07	Sales Q/Q	-94.65%	SMA50	-9.87%	Rel Volume	1.23	Prev Close	14.92
Employees	214	LT Debt/Eq	0.07	Earnings	Mar 04 BMO	SMA200	8.27%	Avg Volume	1.40M	Price	14.03
IPO	Jan 27, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.35% -37.66%	Trades		Volume	1,720,422	Change	-5.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	RBC Capital Mkts	Outperform	$28
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Mar-04-26 04:03PM	EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... (GuruFocus.com) -12.44%
12:36PM	EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
10:36AM	Eyepoint Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:23AM	EyePoint: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-02-26 07:00AM	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-26-26 12:15PM	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-25-26 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
07:00AM	EyePoint Appoints Michael Campbell as Chief Commercial Officer (GlobeNewswire)
Feb-17-26 08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com) +15.22%
07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
05:12PM	Loading…
Feb-13-26 05:12PM	EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program (MarketBeat) +15.22%
Feb-05-26 07:00AM	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 07:00AM	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 (GlobeNewswire)
Dec-22-25 12:00PM	EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know (Zacks) +8.15%
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-17-25 07:00AM	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
08:06AM	Loading…
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
Mar-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-25 02:14AM	Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Mar-05-25 09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +8.22%
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:34AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-25 07:17AM	Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result (GuruFocus.com) +6.29%
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-26-25 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-25-25 07:00AM	EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 07:00AM	EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints (GlobeNewswire)
Jan-30-25 07:00AM	EyePoint to Present at Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.46%
Jan-13-25 07:00AM	EyePoint Provides Company Update and Anticipated Development Milestones for 2025 (GlobeNewswire) -7.07%
Jan-08-25 07:00AM	EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors (GlobeNewswire)
Dec-17-24 07:25AM	EyePoint reports inducement grants under NASDAQ listing rule (TipRanks) +5.39%
07:00AM	EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Nov-13-24 09:55AM	Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? (Zacks)
Nov-12-24 06:45AM	EyePoint price target lowered to $33 from $38 at Baird (TipRanks) -7.42%
Nov-07-24 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:37AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 04:00PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
Oct-29-24 09:47PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:49AM	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-28-24 05:14PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +27.58%

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Option Exercise	8.26	2,438	20,138	2,438	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Sale	17.87	2,438	43,572	0	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Feb 18 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Sale	15.00	2,437	36,555	0	Feb 18 04:07 PM
Lurker Nancy	Director	Jan 06 '26	Option Exercise	0.00	75,133	0	294,346	Jan 07 04:13 PM
Duker Jay S.	President and CEO	Jan 06 '26	Option Exercise	0.00	20,793	0	87,806	Jan 07 04:12 PM
Elston George	Chief Financial Officer	Jan 06 '26	Option Exercise	0.00	15,285	0	96,339	Jan 07 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Option Exercise	8.26	29,250	241,605	42,544	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Sale	17.10	42,544	727,319	0	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	19,667	Jan 06 04:47 PM
Duker Jay S.	President and CEO	Jan 05 '26	Option Exercise	0.00	30,000	0	81,518	Jan 06 04:10 PM
Duker Jay S.	President and CEO	Jan 03 '26	Option Exercise	0.00	65,000	0	74,965	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	15,000	0	85,457	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	76,781	Jan 06 04:10 PM
Lurker Nancy	Director	Jan 05 '26	Option Exercise	0.00	12,666	0	219,213	Jan 06 04:07 PM
Ramiro Ribeiro	Officer	Jan 05 '26	Proposed Sale	17.48	53,792	940,284		Jan 05 04:42 PM
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM
Zaderej Karen L.	Director	Jul 11 '25	Option Exercise	0.00	2,000	0	38,500	Jul 11 04:07 PM
Lurker Nancy	Director	Jul 10 '25	Option Exercise	0.00	11,111	0	216,547	Jul 11 04:06 PM
Duker Jay S.	President and CEO	Jul 10 '25	Option Exercise	0.00	16,667	0	17,653	Jul 11 04:06 PM
Elston George	Chief Financial Officer	May 25 '25	Option Exercise	0.00	7,500	0	83,050	May 27 04:08 PM
Zaderej Karen L.	Director	May 19 '25	Buy	5.99	5,000	29,950	36,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 16 '25	Buy	5.81	5,000	29,050	31,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 15 '25	Buy	5.47	5,000	27,350	26,500	May 15 04:06 PM
Zaderej Karen L.	Director	May 14 '25	Buy	5.42	5,000	27,100	21,500	May 15 04:06 PM

Open in Screener

AXGN

Axogen Inc

Mar 12 • 04:00PM ET

31.76

-0.53 -1.64 %

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: VTI IWM VXF IWO FESM VTWO SCHA IHI VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	1.90%	Shs Outstand	51.90M	Perf Week	8.92%
Market Cap	1.65B	Forward P/E	42.70	EPS next Y	0.74	Insider Trans	-32.82%	Shs Float	50.91M	Perf Month	-7.97%
Enterprise Value	1.67B	PEG	0.85	EPS next Q	0.07	Inst Own	83.18%	Short Float	5.69%	Perf Quarter	3.76%
Income	-15.70M	P/S	7.32	EPS this Y	76.72%	Inst Trans	3.71%	Short Ratio	3.15	Perf Half Y	97.64%
Sales	225.21M	P/B	11.63	EPS next Y	45.12%	ROA	-7.38%	Short Interest	2.89M	Perf YTD	-2.96%
Book/sh	2.73	P/C	36.20	EPS next 5Y	50.37%	ROE	-13.49%	52W High	36.00 -11.78%	Perf Year	82.01%
Cash/sh	0.88	P/FCF	-	EPS past 3/5Y	20.86% 10.54%	ROIC	-8.09%	52W Low	9.22 244.66%	Perf 3Y	319.00%
Dividend Est.	-	EV/EBITDA	2530.87	Sales past 3/5Y	17.57% 14.93%	Gross Margin	74.31%	Volatility	5.91% 5.86%	Perf 5Y	54.85%
Dividend TTM	-	EV/Sales	7.42	EPS Y/Y TTM	-46.89%	Oper. Margin	-3.49%	ATR (14)	1.71	Perf 10Y	517.90%
Dividend Ex-Date	Jan 27, 2010	Quick Ratio	3.31	Sales Y/Y TTM	20.21%	Profit Margin	-6.97%	RSI (14)	49.63	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	5.11	EPS Q/Q	-3081.91%	SMA20	-0.78%	Beta	1.02	Target Price	40.80
Payout	-	Debt/Eq	0.52	Sales Q/Q	21.25%	SMA50	-2.72%	Rel Volume	1.23	Prev Close	32.29
Employees	622	LT Debt/Eq	0.51	Earnings	Feb 24 BMO	SMA200	47.04%	Avg Volume	919.35K	Price	31.76
IPO	Dec 17, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.17% 1.48%	Trades		Volume	1,126,986	Change	-1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-26	Initiated	Wells Fargo	Overweight	$40
Dec-01-25	Initiated	Mizuho	Outperform	$40
Mar-17-25	Initiated	Lake Street	Buy	$30
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50

Show Previous Ratings

Mar-05-26 09:07PM	AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference (MarketBeat)
Feb-24-26 08:03PM	AxoGen, Inc. Q4 2025 Earnings Call Summary (Moby) -8.14%
02:03PM	Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
10:44AM	AxoGen Q4 Earnings Call Highlights (MarketBeat)
09:40AM	AxoGen (AXGN) Q4 Earnings Miss Estimates (Zacks)
07:32AM	Loading…
07:32AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-19-26 07:01AM	Axogen (AXGN) Benefited from Multiple Tailwinds (Insider Monkey)
Feb-17-26 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 07:00AM	Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-22-26 12:42PM	Axogen Prices Upsized $124 Million Stock Offering (Benzinga)
Jan-21-26 11:18PM	Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock (GlobeNewswire)
04:09PM	Axogen Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-15-26 03:07PM	AxoGen Touts Post-BLA Growth Plan, 75%+ Gross Margin Outlook at J.P. Morgan Healthcare Conference (MarketBeat)
Jan-12-26 07:00AM	Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 (GlobeNewswire) -5.85%
07:00AM	Loading…
Dec-17-25 07:00AM	Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) +6.95%
Dec-03-25 08:01PM	Axogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) (GlobeNewswire) +15.97%
Nov-04-25 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 08:15AM	AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates (Zacks) +23.06%
07:13AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-15-25 07:00AM	Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 (GlobeNewswire)
Oct-06-25 08:04AM	CLPT Expands Into Robotic System Supporting Cell and Gene Therapies (Zacks)
Sep-26-25 09:21AM	GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent (Zacks)
Sep-25-25 09:24AM	Masimo Completes Divestment of Consumer Audio Business to HARMAN (Zacks)
Sep-23-25 08:21AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Aug-28-25 09:55AM	Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 04:04PM	Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted (Investor's Business Daily) -9.04% +9.60%
10:39AM	Loading…
10:39AM	FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months (Benzinga)
06:40AM	Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft (GlobeNewswire)
Aug-20-25 09:13AM	Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin (Insider Monkey)
Aug-13-25 12:08PM	Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 (Insider Monkey)
Aug-12-25 09:55AM	Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know (Zacks)
Aug-05-25 08:15AM	AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:21AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 07:10AM	Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-29-25 04:10PM	Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
10:00AM	AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-22-25 04:05PM	Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 (GlobeNewswire) +8.01% +7.34%
Jul-02-25 10:06PM	Axogen Showcases Nerve Repair Vision at Goldman Sachs (Insider Monkey)
May-28-25 08:00AM	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-25 09:35AM	AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-09-25 09:45AM	Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline (Zacks) -9.73%
09:30AM	MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off (Zacks)
03:08AM	Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... (GuruFocus.com)
May-08-25 08:30AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -23.18%
07:28AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Reports 2025 First Quarter Financial Results (GlobeNewswire)
07:00AM	Axogen Announces Chief Financial Officer Transition (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
01:09PM	COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised (Zacks)
12:31PM	AxoGen Q1 2025 Earnings Preview (Seeking Alpha)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
Apr-24-25 08:04AM	Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 (GlobeNewswire)
Mar-31-25 03:03PM	Stryker Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Mar-25-25 11:12AM	Axogen: LT Bullish, But Outcomes Weighted To Downside, At This Point (SeekingAlpha)
Mar-24-25 08:00AM	Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Began Marc A	EVP & General Counsel	Mar 01 '26	Option Exercise	0.00	11,250	0	54,562	Mar 02 06:15 PM
Wendell Amy McBride	Director	Dec 16 '25	Option Exercise	6.91	43,684	301,963	137,510	Dec 17 04:25 PM
Wendell Amy McBride	Director	Dec 16 '25	Sale	29.31	43,684	1,280,465	93,826	Dec 17 04:25 PM
Weiler Kathy Johnson	Director	Dec 16 '25	Option Exercise	6.99	40,073	280,150	46,653	Dec 17 04:25 PM
Weiler Kathy Johnson	Director	Dec 16 '25	Sale	29.55	46,653	1,378,476	0	Dec 17 04:25 PM
Hartley Lindsey Marie	CFO	Dec 15 '25	Option Exercise	8.27	14,812	122,495	46,188	Dec 17 04:24 PM
Hartley Lindsey Marie	CFO	Dec 15 '25	Sale	29.86	14,812	442,294	31,376	Dec 17 04:24 PM
Amy McBride-Wendell	Director	Dec 16 '25	Proposed Sale	29.31	43,684	1,280,461		Dec 16 05:03 PM
KATHY WEILER	Director	Dec 16 '25	Proposed Sale	29.55	46,653	1,378,484		Dec 16 04:27 PM
LINDSEY MARIE HARTLEY	Officer	Dec 15 '25	Proposed Sale	29.86	14,812	442,294		Dec 15 05:38 PM
DALE MICHAEL D	Chief Executive Officer	Dec 10 '25	Sale	30.00	25,000	750,000	63,537	Dec 12 04:06 PM
Began Marc A	EVP & General Counsel	Dec 11 '25	Sale	30.00	13,222	396,660	18,285	Dec 12 04:05 PM
MARC BEGAN	Officer	Dec 11 '25	Proposed Sale	30.00	13,222	396,660		Dec 11 04:08 PM
DALE MICHAEL D	Chief Executive Officer	Dec 09 '25	Sale	31.21	61,463	1,918,137	88,537	Dec 10 05:21 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Option Exercise	8.73	25,108	219,223	25,108	Dec 10 05:20 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Sale	30.98	25,108	777,771	0	Dec 10 05:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Dec 09 '25	Sale	31.21	19,517	609,087	241,132	Dec 10 05:20 PM
Kemp Jens	Chief Marketing Officer	Dec 09 '25	Sale	31.21	8,156	254,532	46,030	Dec 10 05:20 PM
Began Marc A	EVP & General Counsel	Dec 09 '25	Sale	31.21	9,278	289,548	31,507	Dec 10 05:19 PM
THOMAS PAUL	Director	Dec 09 '25	Sale	29.61	21,399	633,710	13,528	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Option Exercise	6.30	11,891	74,913	25,032	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Option Exercise	6.30	8,545	53,834	21,686	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Sale	31.24	23,693	740,203	13,141	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Sale	29.98	21,686	650,190	0	Dec 10 05:19 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Option Exercise	13.82	25,000	345,400	45,763	Dec 10 05:18 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Sale	31.56	14,387	454,005	31,376	Dec 10 05:18 PM
MICHAEL DALE	Officer	Dec 10 '25	Proposed Sale	30.00	25,000	750,000		Dec 10 04:19 PM
PAUL THOMAS	Director	Dec 09 '25	Proposed Sale	29.61	21,399	633,710		Dec 09 04:40 PM
JOSEPH A TYNDALL	Director	Dec 09 '25	Proposed Sale	30.98	25,108	777,771		Dec 09 04:39 PM
JOHN H JOHNSON	Director	Dec 09 '25	Proposed Sale	29.98	21,686	650,186		Dec 09 04:05 PM
JOHN H JOHNSON	Director	Dec 08 '25	Proposed Sale	31.24	23,693	740,207		Dec 08 06:21 PM
LINDSEY MARIE HARTLEY	Officer	Dec 08 '25	Proposed Sale	31.56	14,387	454,009		Dec 08 04:32 PM
Burke William P. Mr.	Director	Nov 10 '25	Option Exercise	8.14	19,227	156,508	19,327	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Option Exercise	8.14	3,591	29,231	3,691	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 10 '25	Sale	24.01	19,227	461,640	100	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Sale	24.02	3,591	86,249	100	Nov 13 04:31 PM
WILLIAM BURKE	Director	Nov 11 '25	Proposed Sale	24.00	3,591	86,184		Nov 12 07:05 AM
WILLIAM BURKE	Director	Nov 10 '25	Proposed Sale	23.57	19,227	453,180		Nov 10 04:30 PM
Burke William P. Mr.	Director	Nov 05 '25	Option Exercise	8.14	11,431	93,048	11,531	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Option Exercise	8.14	5,347	43,525	5,447	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 05 '25	Sale	24.05	11,431	274,893	100	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Sale	24.01	5,347	128,371	100	Nov 07 04:52 PM
WILLIAM BURKE	Director	Nov 06 '25	Proposed Sale	23.38	5,347	125,013		Nov 06 04:20 PM
WILLIAM BURKE	Director	Nov 05 '25	Proposed Sale	23.77	11,431	271,715		Nov 05 04:20 PM
Burke William P. Mr.	Director	Oct 29 '25	Option Exercise	7.21	40,235	289,911	20,536	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Option Exercise	7.04	18,248	128,466	18,348	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 29 '25	Sale	20.55	40,235	827,013	100	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Sale	23.00	18,248	419,704	100	Oct 31 04:09 PM
WILLIAM BURKE	Director	Oct 30 '25	Proposed Sale	22.25	18,248	406,018		Oct 30 04:16 PM
WILLIAM BURKE	Director	Oct 29 '25	Proposed Sale	18.08	36,162	653,809		Oct 29 04:25 PM
Burke William P. Mr.	Director	Oct 22 '25	Sale	18.02	1,457	26,252	100	Oct 24 04:09 PM
Burke William P. Mr.	Director	Oct 22 '25	Proposed Sale	18.02	1,457	26,252		Oct 22 04:41 PM
Burke William P. Mr.	Director	Oct 06 '25	Sale	18.00	736	13,249	1,557	Oct 07 05:18 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	14,571	265,283	2,293	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	7,600	138,367	0	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	7,620	137,200	16,864	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	2,400	43,224	7,600	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 06 '25	Proposed Sale	18.00	736	13,249		Oct 06 04:54 PM
WILLIAM BURKE	Director	Oct 03 '25	Proposed Sale	17.88	14,937	267,074		Oct 03 04:36 PM
Burke William P. Mr.	Director	Oct 03 '25	Proposed Sale	18.25	11,307	206,317		Oct 03 04:29 PM
Burke William P. Mr.	Director	Oct 02 '25	Proposed Sale	18.01	2,400	43,224		Oct 02 04:24 PM
WILLIAM BURKE	Director	Oct 02 '25	Proposed Sale	17.87	7,620	136,169		Oct 02 04:21 PM
DeVinney Erick Wayne	Chief Innovation Officer	Sep 16 '25	Sale	16.29	1,137	18,522	220,649	Sep 16 05:22 PM
Weiler Kathy Johnson	Director	Jun 09 '25	Sale	10.61	4,073	43,215	6,580	Jun 11 04:27 PM
Levine Alan M	Director	Jun 09 '25	Sale	10.61	4,073	43,215	36,743	Jun 11 04:26 PM
Wendell Amy McBride	Director	Jun 09 '25	Sale	10.61	4,073	43,215	93,826	Jun 11 04:26 PM
Burke William P. Mr.	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,484	Jun 11 04:25 PM
NEELS GUIDO J	Director	Jun 09 '25	Sale	10.61	4,073	43,215	86,743	Jun 11 04:24 PM
JOHNSON JOHN	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,943	Jun 11 04:23 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Option Exercise	6.56	11,586	75,952	26,931	Jun 11 04:22 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Sale	10.72	26,931	288,700	0	Jun 11 04:22 PM
JOSEPH A TYNDALL	Director	Jun 10 '25	Proposed Sale	10.72	26,931	288,814		Jun 10 05:41 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Option Exercise	6.30	12,850	80,955	35,407	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Sale	11.20	20,062	224,694	15,345	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 19 '25	Sale	11.63	2,525	29,366	22,557	May 23 04:12 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Proposed Sale	11.15	32,339	360,580		May 22 05:14 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '25	Option Exercise	0.00	32,462	0	232,873	Mar 19 05:24 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 19 '25	Sale	17.50	15,111	264,442	217,762	Mar 19 05:24 PM

EYPT

EyePoint Inc

AXGN

Axogen Inc

Upgrade your FINVIZ experience